BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9583615)

  • 1. On the issue of cross-resistance between protease inhibitors.
    Birch C
    AIDS; 1998 Apr; 12(6):680-1. PubMed ID: 9583615
    [No Abstract]   [Full Text] [Related]  

  • 2. [Resistance to protease inhibitors].
    Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 4. Protease inhibitors: resistance, resistance, resistance.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 6. [Primary resistance to antiretroviral agents].
    Soriano V; María Miró J; Guerrero A
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):22-5. PubMed ID: 11428054
    [No Abstract]   [Full Text] [Related]  

  • 7. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
    Pérez-Alvarez L; Cuevas MT; Villahermosa ML; Pedreira JD; Manjón N; Herrero I; López-Calvo S; Delgado E; de Parga EV; Medrano L; Thomson MM; Taboada JA; Nájera R;
    J Hum Virol; 2001; 4(1):35-8. PubMed ID: 11213931
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Murphy MD; Marousek GI; Chou S
    J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral resistance to protease inhibitors.
    Smart T
    GMHC Treat Issues; 1995 Jun; 9(6):1, 4-5. PubMed ID: 11362685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human immunodeficiency virus and antiretroviral therapy resistance].
    Quirós E; Torti C; Carosi G
    Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
    [No Abstract]   [Full Text] [Related]  

  • 12. Nelfinavir (Viracept).
    Res Initiat Treat Action; 2000 Mar; 6(1):30-1. PubMed ID: 11708185
    [No Abstract]   [Full Text] [Related]  

  • 13. Indinavir (Crixivan).
    Res Initiat Treat Action; 2000 Mar; 6(1):28-9. PubMed ID: 11708184
    [No Abstract]   [Full Text] [Related]  

  • 14. Ritonavir (Norvir).
    Res Initiat Treat Action; 2000 Mar; 6(1):26-7. PubMed ID: 11708183
    [No Abstract]   [Full Text] [Related]  

  • 15. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 16. Amprenavir (Agenerase).
    Res Initiat Treat Action; 2000 Mar; 6(1):32-3. PubMed ID: 11708186
    [No Abstract]   [Full Text] [Related]  

  • 17. Saquinavir (Fortovase or Invirase).
    Res Initiat Treat Action; 2000 Mar; 6(1):24-5. PubMed ID: 11708182
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Zachary KC; Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.